Research Topics
| S NovelloSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokersS Novello
University of Turin, Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Orbassano Turin, Italy
Ann Oncol 16:1662-6. 2005....- Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancerG V Scagliotti
Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedliera S Luigi, Orbassano, Italy
Lung Cancer 25:39-46. 1999.... - ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabineP Ceppi
Thoracic Oncology Unit, Orbassano, Torino, Italy
Ann Oncol 17:1818-25. 2006..Prospective pharmacogenomic studies represent a research priority in early and advanced NSCLC... - Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine aloneS Novello
Department of Clinical and Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy
Ann Oncol 18:903-8. 2007.... - Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancerS Novello
Department of Clinical and Biological Sciences, University of Torino, Azienda Ospedaliera S. Luigi, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
Lung Cancer 34:261-9. 2001..CONCLUSION: In advanced NSCLC, the combination carboplatin-paclitaxel at doses of AUC 6 mg/ml per minute and 225 mg/ml every 3 weeks, is both active and relatively well-tolerated... - Prevalence of adrenal incidentaloma in a contemporary computerized tomography seriesS Bovio
Internal Medicine I, Department of Biological and Clinical Sciences, ASO San Luigi, University of Turin, Italy
J Endocrinol Invest 29:298-302. 2006..Notwithstanding that our subjects were at increased risk of lung cancer, the rate of adrenal metastases was low. We think that the present results can be generalized even if we may disclose the lack of histological diagnosis... - Multidrug resistance in non-small-cell lung cancerG V Scagliotti
University of Turin, Department of Clinical and Biological Sciences, Azienda Ospedaliera S Luigi Orbassano, Torino, Italy
Ann Oncol 10:S83-6. 1999..In lung cancer the role of the different forms of multidrug resistance is complex and only partially understood... - Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in ItalyS Novello
Department of Clinical and Biological Sciences, University of Torino, Turin, Italy
Lung Cancer 48:379-87. 2005..Based on resource consumption in a clinical trial, Gem/Cis had the lowest overall mean costs of the three chemotherapy regimens. Gem/Cis therefore has the potential to save costs in the treatment of advanced NSCLC in Italy... 
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerS Novello
Department of Clinical and Biological Sciences, Thoracic Oncology Unit, University of Turin, Orbassano, Turin, Italy
Br J Cancer 101:1543-8. 2009..Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC)...- Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancerG Selvaggi
Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
Ann Oncol 15:28-32. 2004..We designed a prospective study to test epidermal growth factor receptor (EGFR) expression by immunohistochemistry (IHC) in resected stage I-IIIA non-small-cell lung cancer (NSCLC) and to correlate overexpression with survival... - State of the art in mesotheliomaG V Scagliotti
University of Turin, Department of Clinical and Biological Sciences, S. Luigi Hospital, Orbassano (Torino, Italy
Ann Oncol 16:ii240-5. 2005 - Current status of adjuvant chemotherapy in NSCLCG V Scagliotti
Department of Clinical and Biological Sciences, S. Luigi Hospital, Thoracic Oncology Unit, University of Turin, Torino, Italy
Ann Oncol 17:v62-3. 2006 
Functional imaging in predicting response to antineoplastic agents and molecular targeted therapies in lung cancer: a review of existing evidenceS Novello
Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, AOU San Luigi Orbassano, Italy
Crit Rev Oncol Hematol 83:208-15. 2012..This article discusses the assessment of treatment response in NSCLC patients using functional imaging, and emphasizes advantages and limitations in clinical management...- Role of erythropoietin in the treatment of lung cancer associated anaemiaG V Scagliotti
Department of Clinical and Biological Sciences, University of Torino, Regione Gonzole 10, Azienda Ospedaliera S Luigi, 10043 Orbassano, Torino, Italy
Lung Cancer 34:S91-4. 2001..This 'functional' level would be in keeping with the body's physiological erythropoietin response... - Chemo-radiotherapy in lung cancer: state of the art with focus on the elderly populationC Mantovani
Department of Medical and Surgical Sciences, Radiotherapy Unit, University of Turin, Italy
Ann Oncol 17:ii61-63. 2006 - A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancerM H Cullen
Cancer Centre, Queen Elizabeth Hospital, University Hospital Birmingham, Birmingham, UK
Ann Oncol 19:939-45. 2008..This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy... - A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyF Cappuzzo
Division of Medical Oncology, Bellaria Hospital, Bologna, Via Altura 3, 40139 Bologna, Italy
Lung Cancer 52:319-25. 2006..This study has been designed in order to explore two different approaches of gemcitabine dose intensification in patients with advanced NSCLC... - Women and lung cancerS Novello
, Turin
Ann Oncol 17:ii79-82. 2006 - Treatment of advanced non-small cell lung cancerL De Petris
5th Pneumo-Oncology Unit, Deparment of Lung Diseases, S. Camillo-Forlanini Hospitals, Rome, Italy
Ann Oncol 17:ii36-41. 2006..With pharmacogenomics it would then be possible to accurately predict patient outcome and tailor the treatment strategy according to the geno-phenotype of single patients... - Cytotoxic chemotherapy in advanced non-small cell lung cancerG V Scagliotti
Monaldi Arch Chest Dis 63:181-3. 2005 - Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancerF Cappuzzo
Division of Medical Oncology, Bellaria Hospital, Bologna, Via Altura 3, 40139 Bologna, Italy
Br J Cancer 93:29-34. 2005..Our results show that gemcitabine-oxaliplatin chemotherapy is active and well tolerated in patients with advanced NSCLC, deserving further study, especially for patients not eligible to receive cisplatin... - Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancerC Monnerat
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
Ann Oncol 15:316-23. 2004..CONCLUSIONS: The results of the present study indicate that PKC412 at a dose of 50 mg/day can be safely added to cisplatin and gemcitabine in patients with advanced non-small-cell lung cancer... - Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinomaS Faivre
Department of Medicine, Institut Gustave-Roussy, Villejuif, France
Ann Oncol 13:1479-89. 2002..The RD was gemcitabine 1500 mg/m(2) and oxaliplatin 85 mg/m(2) every 2 weeks. Promising antitumor activity was reported in patients with NSCLC and platinum-pretreated OC, and thus, deserves further evaluation... - Use of chemo-radiotherapy in locally advanced non-small cell lung cancerS Novello
Department of Medicine, Institut Gustave-Roussy, rue Camille-Desmoulins, 94805 Villejuif Cedex, France
Eur J Cancer 38:292-9. 2002..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity... - Is there a standard strategy in the management of locally advanced non-small cell lung cancer?S Novello
Departement of Medicine, Institut Gustave Roussy, Villejuif, France
Lung Cancer 34:S9-14. 2001..Current developments aim to optimise individual components of combined modality schedules, increase their synergism and minimise toxicity... - European perspectives on paclitaxel/platinum-based therapy for advanced non-small cell lung cancerS Novello
Department of Medicine, Institut Gustave Roussy, Villejuif, France
Semin Oncol 28:3-9. 2001..The use of paclitaxel in regimens without platinum and in triplet combinations is also being studied, and the optimal manner in which to administer this active agent clearly is of interest...